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Hypertension in pregnancy and statistical power
Hypertension in pregnancy is a major cause ofmaternal and fetal morbidity. I Preeclampsia,eclampsia, intrauterine growth retardation, and
perinatal mortality are adverse effects associated with
hypertension.
Approximately 10 percent of pregnant women are at
risk for complications attributable to high arterial blood
pressure.2 Although the treatment of hypertension reduces
the maternal risks,3 the benefits for the fetus are not yet
c1ear.4
The treatment of hypertension crises, one of the most
dangerous types of hypertension in pregnancy may be
obtained with efficacy using low dose nifedipine (5 mg per
oral), or hydrazaline (5 mg IM). Reducing the dosage is
aimed at decreasing the risks of maternal hypotension and
fetal death.5.6
Both drugs have about 90 percent efficacy in reducing
blood pressure, but it is not known wich drug carriers less
risk of adverse effects for the fetus. Suppose that one percent
of fetal deaths could be attributed to one drug, and the other
drug could be attributed with 0.5 percent; that means a 50
percent less chance of fetal deaths. In order to have 90
percent power to detect the refered difference on the
fetal attributable mortality rate to each of these drugs,
a study of 14,000 women with hypertensive crises would
be required.7
Although doing a randomized clinical trial of such
magnitude would be very difficult, it would certainly not
be impossible - if the question were considered relevant
for researchers, and more importantly, for funders. Similar
situations, as are the cases of drugs adverse effects are
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common in medical literature, and important because they
represent human suffering and death.
A proposal for a randomized clinical trial has been
prepared by the Eclampsia Trial Group, aimed at comparing
magnesium sulfate with placebo. The sample size is estimated
at 14,000 cases. The trial would be collaborati ve, with various
groups in Europe and developing countries participating. The
effort is worthwhile, as the prevention of eclampsia could
prevent about 50,000 maternal deaths annually, 99 percent
of which occur in the developing world.x
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